Gooseberry Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 136.68%
- Profit Growth 546.96%
- Ebitda 68.19%
- Net Worth 1876.16%
- Total Assets 93.07%
About Gooseberry Pharmaceuticals
Gooseberry Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 February 2019 (Five years and 11 months 29 days old ). Its registered office is in North 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sumita Acharya and Arup Acharya serve as directors at the Company.
Company Details
-
Location
North 24 Parganas, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U51909WB2019PTC230469
-
Company No.
230469
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Feb 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Gooseberry Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumita Acharya
|
Director | 15-Feb-2019 | Current |
|
Arup Acharya
|
Director | 31-Oct-2019 | Current |
Financial Performance of Gooseberry Pharmaceuticals.
Gooseberry Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 136.68% increase. The company also saw a substantial improvement in profitability, with a 546.96% increase in profit. The company's net worth Soared by an impressive increase of 1876.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gooseberry Pharmaceuticals?
Unlock access to Gooseberry Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gooseberry Pharmaceuticals?
Gooseberry Pharmaceuticals has a workforce of 20 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gooseberry Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gooseberry Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
